Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409458 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
A Phase 1 study, sponsored by Promontory Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03409458 is a Phase 1 study that has completed, run by Promontory Therapeutics. The registered enrollment target is 68 participants.
The verdict
NCT03409458, a Phase 1 study, has completed, sponsored by Promontory Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer who will be treated at the RP2D.
Interventions
- DRUG PT-112
- BIOLOGICAL avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409458
The ClinicalTrials.gov registry entry for NCT03409458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promontory Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PT-112 is the first listed.
NCT03409458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409458 about?
NCT03409458 is a clinical study titled "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab". This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose...
What is the current status of trial NCT03409458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-04-24. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT03409458?
The interventions under investigation include: PT-112 (DRUG), avelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03409458?
This trial is sponsored by Promontory Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.